RTP Mobile Logo
Beyond the Guidelines: Biomarker Assessment and Targeted Therapy for Metastatic Colorectal Cancer (Video Program)
Released November 2020

Featuring a roundtable discussion with Drs Scott Kopetz, Wells A Messersmith and Alan P Venook. (Video Program)

CE Disclosures and Faculty Information

    This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of gastrointestinal cancers.


    • Coordinate comprehensive biomarker analysis for patients diagnosed with metastatic colorectal cancer (mCRC), and use the results to guide evidence-based care.
    • Develop a long-term care plan for individuals with mCRC, considering patient and disease characteristics, including biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals of treatment.
    • Appreciate published research data documenting the efficacy of the BRAF inhibitor encorafenib in combination with the EGFR inhibitor cetuximab for patients with relapsed/refractory mCRC and a BRAF V600E mutation in order to optimally incorporate this therapeutic strategy into current clinical algorithms.
    • Appraise the FDA approvals of nivolumab, pembrolizumab and the combination of nivolumab/ipilimumab for patients with microsatellite instability-high or mismatch repair-deficient mCRC, and appropriately integrate these agents into current nonresearch treatment algorithms.
    • Educate patients with mCRC about side effects associated with approved and investigational targeted agents and immunotherapies, and develop a plan to optimally recognize and manage these toxicities.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue

    CME credit is no longer available for this issue

    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Scott Kopetz, MD, PhD
    Professor and Deputy Chair
    Department of Gastrointestinal Medical Oncology
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    No financial interests or affiliations to disclose.

    Wells A Messersmith, MD
    Professor and Head, Division of Medical Oncology
    Associate Director for Translational Research
    University of Colorado Cancer Center
    Aurora, Colorado

    Contracted Research: Aduro Biotech, ALX Oncology, AstraZeneca Pharmaceuticals LP, BeiGene, D3 Pharma, Gossamer Bio, Immunomedics Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics, QED Therapeutics.

    Alan P Venook, MD
    The Madden Family Distinguished Professor of
    Medical Oncology and Translational Research
    Shorenstein Associate Director, Program Development
    Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco
    San Francisco, California

    Advisory Committee: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Roche Laboratories Inc; Contracted Research: Amgen Inc, Genentech, a member of the Roche Group, Merck, Roche Laboratories Inc; Data and Safety Monitoring Board/Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc.

    EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.

    This activity is supported by an educational grant from Pfizer Inc.

    Release date: November 2020
    Expiration date: November 2021

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Biomarkers in Metastatic Colorectal Cancer (mCRC)

Current and Emerging Role of Immune Checkpoint Inhibitors in the Management of mCRC

Expanding Therapeutic Options for Patients with mCRC with BRAF V600E Mutations

HER2 and Other Emerging Biomarkers in mCRC

Impact of Tumor Location on First-Line Treatment; Selection of Biologic Agent

Select Publications